QuantumCyte
QuantumCyte is a technology platform company specializing in cellular enrichment of tissue biopsies to increase nucleic acid purity for downstream multi-omic applications. Their flagship product, QCPRECISE™, combines AI-based digital pathology with molecular analysis to improve tumor purity and enable more reliable and actionable cancer research and clinical diagnostics. The platform eliminates manual scraping, increases throughput compared to laser capture microdissection, and rescues previously rejected samples with low tumor content. QuantumCyte collaborates with major clinical labs, academic translational research institutions, and pharmaceutical companies to advance cancer and solid tissue disease research and diagnostics. Their business model includes technology access services where customers send samples to their Sunnyvale, CA lab for processing.
QuantumCyte
QuantumCyte is a technology platform company specializing in cellular enrichment of tissue biopsies to increase nucleic acid purity for downstream multi-omic applications. Their flagship product, QCPRECISE™, combines AI-based digital pathology with molecular analysis to improve tumor purity and enable more reliable and actionable cancer research and clinical diagnostics. The platform eliminates manual scraping, increases throughput compared to laser capture microdissection, and rescues previously rejected samples with low tumor content. QuantumCyte collaborates with major clinical labs, academic translational research institutions, and pharmaceutical companies to advance cancer and solid tissue disease research and diagnostics. Their business model includes technology access services where customers send samples to their Sunnyvale, CA lab for processing.
TL;DR
Headquarters: Sunnyvale, California
Product: QCPRECISE™ automated scan-print-extract microdissection platform
Founded: 2013
Founders: John Butler; Bidhan Chaudhuri, PhD
Industry: Biotechnology / molecular pathology
Company Overview
Problem Domain
Enrichment of tumor cells and improvement of nucleic acid purity from tissue biopsies to enable reliable molecular analysis for cancer research and diagnostics.
Founded
2013
Industry
Biotechnology
Funding Track Record
Crunchbase lists multiple funding rounds and Series A status
Investor Signal
“Participation from SOSV / IndieBio and North South Ventures”